Skip to main content

Main menu

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums

User menu

  • My alerts

Search

  • Advanced search
The College of Family Physicians of Canada
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums
  • My alerts
The College of Family Physicians of Canada

Advanced Search

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • RSS feeds
  • Follow cfp Template on Twitter
Research ArticlePractice

Statin-induced diabetes: too sweet a deal?

Ricky Turgeon and G. Michael Allan
Canadian Family Physician July 2013, 59 (7) e311;
Ricky Turgeon
Pharmacist currently completing an additional training residency year in Vancouver, BC.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G. Michael Allan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • eLetters
  • Info & Metrics
  • PDF
Loading

Clinical question

Do statins increase the risk of diabetes, and does this worsen outcomes?

Bottom line

Statins modestly increase blood glucose levels, which leads to 1 in 250 or so patients crossing the “diabetic threshold” in a 5-year period. Pre-existing elevated blood glucose levels, other diabetes risk factors, or higher statin doses might slightly increase the risk. This should not change statin prescribing, as statins reduce cardiovascular events and all-cause mortality in appropriate patients.

Evidence

  • Statin vs no statin: meta-analysis1 of 13 RCTs with 91 140 patients at high risk of or with cardiovascular disease.

    • -New diabetes over a mean of 4 years: 4.9% of those taking statins vs 4.5% of the control patients; number needed to harm was 250.

  • High vs moderate- or low-dose statin (eg, 80 mg vs 10 mg of atorvastatin): meta-analysis2 of 5 RCTs with 32 752 patients with cardiovascular disease.

    • -New diabetes over a mean of 5 years: 8.8% of those in the high-dose group vs 8.0% in the moderate- or low-dose group; number needed to harm was 125.

Context

  • Diagnosis of type 2 diabetes is largely based on crossing an arbitrary laboratory threshold, like fasting plasma glucose (FPG) of 7.0 mmol/L or greater.3

    • -Elevated baseline FPG is a risk factor for developing diabetes with statins.4

    • -In an observational study, FPG increased by 0.1 mmol/L at 2 years in those without diabetes taking statins.5

    • -Thus, the increased diagnoses of diabetes in statin users are likely, in good part, from patients with borderline glucose levels crossing the diagnostic cutoff.

  • Despite the increases in blood glucose, statins reduce important clinical outcomes including mortality in patients with appropriate indications.6

    • -In the Heart Protection Study (mostly secondary prevention),7 for every 1 person newly diagnosed with diabetes due to statin use, 5 deaths, 6 nonfatal myocardial infarctions, and 4 strokes were prevented in 5 years.

  • Similar pooled RCT evidence shows an increased risk of diabetes with thiazides and β-blockers vs placebo or other antihypertensive medications.8

    • -Thiazides9 and β-blockers (in appropriate patients)10 also provide net benefit.

Implementation

Patients concerned about the increased risk of diabetes with statins should have the risk put in context. Statins increase the risk of diabetes by about 11%, while hypertension and obesity increase diabetes risk by approximately 100% and 200%, respectively.1,11,12 Alternatively, it might be explained (using data from the JUPITER trial) that patients receiving statins are diagnosed with diabetes on average about 5 weeks sooner than nonusers.13 Most important, for every person diagnosed with diabetes due to a small increase in blood glucose they will not feel, 2 to 15 patients (depending on risk) will avoid serious outcomes like stroke, heart attack, and death.7,13

Notes

Tools for Practice articles in Canadian Family Physician (CFP) are adapted from articles published on the Alberta College of Family Physicians (ACFP) website, summarizing medical evidence with a focus on topical issues and practice-modifying information. The ACFP summaries and the series in CFP are coordinated by Dr G. Michael Allan, and the summaries are co-authored by at least 1 practising family physician and are peer reviewed. Feedback is welcome and can be sent to toolsforpractice{at}cfpc.ca. Archived articles are available on the ACFP website: www.acfp.ca.

Footnotes

  • The opinions expressed in Tools for Practice articles are those of the authors and do not necessarily mirror the perspective and policy of the Alberta College of Family Physicians.

  • Copyright© the College of Family Physicians of Canada

References

  1. ↵
    1. Sattar N,
    2. Preiss D,
    3. Murray HM,
    4. Welsh P,
    5. Buckley BM,
    6. de Craen AJ,
    7. et al
    . Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010;375(9716):735-42. Epub 2010 Feb 16.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Preiss D,
    2. Seshasai SR,
    3. Welsh P,
    4. Murphy SA,
    5. Ho JE,
    6. Waters DD,
    7. et al
    . Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 2011;305(24):2556-64.
    OpenUrlCrossRefPubMed
  3. ↵
    1. American Diabetes Association
    . Diagnosis and classification of diabetes mellitus. Diabetes Care 2013;36(Suppl 1):S67-74.
    OpenUrlFREE Full Text
  4. ↵
    1. Waters DD,
    2. Ho JE,
    3. DeMicco DA,
    4. Breazna A,
    5. Arsenault BJ,
    6. Wun CC,
    7. et al
    . Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. J Am Coll Cardiol 2011;57(14):1535-45.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Sukhija R,
    2. Prayaga S,
    3. Marashdeh M,
    4. Bursac Z,
    5. Kakar P,
    6. Bansal D,
    7. et al
    . Effect of statins on fasting plasma glucose in diabetic and nondiabetic patients. J Investig Med 2009;57(3):495-9.
    OpenUrlPubMed
  6. ↵
    1. Wilt TJ,
    2. Bloomfield HE,
    3. MacDonald R,
    4. Nelson D,
    5. Rutks I,
    6. Ho M,
    7. et al
    . Effectiveness of statin therapy in adults with coronary heart disease. Arch Intern Med 2004;164(13):1427-36.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Heart Protection Study Collaboration Group
    . MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360(9326):7-22.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Elliott WJ,
    2. Meyer PM
    . Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007;369(9557):201-7. Erratum in: Lancet 2007;369(9572):1518.
    OpenUrlCrossRefPubMed
  9. ↵
    1. ALLHAT Collaborative Research Group
    . Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288(23):2981-97. Errata in: JAMA 2004;291(18):2196, JAMA 2003;289(2):178.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Ko DT,
    2. Hebert PR,
    3. Coffey CS,
    4. Curtis JP,
    5. Foody JM,
    6. Sedrakyan A,
    7. et al
    . Adverse effects of beta-blocker therapy for patients with heart failure: a quantitative overview of randomized trials. Arch Intern Med 2004;164(13):1389-94.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Conen D,
    2. Ridker PM,
    3. Mora S,
    4. Buring JE,
    5. Glynn RJ
    . Blood pressure and risk of developing type 2 diabetes mellitus: the Women’s Health Study. Eur Heart J 2007;28(23):2937-43.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Lindström J,
    2. Tuomilehto J
    . The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes Care 2003;26(3):725-31.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Ridker PM,
    2. Pradhan A,
    3. MacFadyen G,
    4. Libby P,
    5. Glynn RJ
    . Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 2012;380(9841):565-71.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Canadian Family Physician: 59 (7)
Canadian Family Physician
Vol. 59, Issue 7
1 Jul 2013
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on The College of Family Physicians of Canada.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Statin-induced diabetes: too sweet a deal?
(Your Name) has sent you a message from The College of Family Physicians of Canada
(Your Name) thought you would like to see the The College of Family Physicians of Canada web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Statin-induced diabetes: too sweet a deal?
Ricky Turgeon, G. Michael Allan
Canadian Family Physician Jul 2013, 59 (7) e311;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
Statin-induced diabetes: too sweet a deal?
Ricky Turgeon, G. Michael Allan
Canadian Family Physician Jul 2013, 59 (7) e311;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Clinical question
    • Bottom line
    • Evidence
    • Context
    • Implementation
    • Notes
    • Footnotes
    • References
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Lignes directrices simplifiees sur les lipides: Prevention et prise en charge des maladies cardiovasculaires en soins primaires
  • Simplified lipid guidelines: Prevention and management of cardiovascular disease in primary care
  • Does ezetimibe modify clinical outcomes?
  • Google Scholar

More in this TOC Section

Practice

  • Is 45 the new 50 in colorectal cancer screening?
  • Approach to diagnosis and management of childhood attention deficit hyperactivity disorder
  • Determining if and how older patients can safely stay at home with additional services
Show more Practice

Tools for Practice

  • Bronchodilators or inhaled corticosteroids for postinfectious cough
  • Intrauterine devices for menorrhagia
  • Topical treatments for anal fissure
Show more Tools for Practice

Similar Articles

Navigate

  • Home
  • Current Issue
  • Archive
  • Collections - English
  • Collections - Française

For Authors

  • Authors and Reviewers
  • Submit a Manuscript
  • Permissions
  • Terms of Use

General Information

  • About CFP
  • About the CFPC
  • Advertisers
  • Careers & Locums
  • Editorial Advisory Board
  • Subscribers

Journal Services

  • Email Alerts
  • Twitter
  • RSS Feeds

Copyright © 2023 by The College of Family Physicians of Canada

Powered by HighWire